View a one-page version for printing.
SWOG Update
April 2010

Contents  
Welcome to the April 2010 SWOG Update.

For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to communications@swog.org.

View a one-page version for printing.
 
Study Updates  
S0941: TKIs against biliary cancers
bile ducts illustration Just launched, S0941 tests combined erlotinib and sorafenib on patients with unresectable or metastasized gallbladder carcinoma or cholangiocarcinoma. [more]
 
Share |
Untitled Document

Recent and Upcoming SWOG Abstracts

ABSTRACTS

Presented

S0000

Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill- Stevens, S Moody-Thomas, J Probstfield, SJ Hamilton, R Campbell, K Anderson, L Minasian. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0000

Infrastructure for successful recruitment when conducting a multi-site clinical trial: the SELECT experience. KB Anderson, ED Cook, SJ Hamilton, LM Minasian, JA Hermos, JL Probstfield. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0000

S0000 The role of a community based organization in a large prevention trial. SJ Hamilton, ED Cook, KB Anderson, JQ Sheats. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0727

Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. PA Philip, BH Goldman, RK Ramanathan, H Lenz, AM Lowy, RP Whitehead, S Iqbal, VM Chung, JK Benedetti, CD Blanke. 2010 Gastrointestinal Cancers Symposium (January 22-24, 2010, Orlando, FL), abst. #233 (poster).

Accepted

S8814

Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials. KS Albain, WE Barlow, S Shak, GN Hortobagyi, DF Hayes. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S9304

Intratumoral gene expression levels of TP (Thymidine phosphorylase)) and VEGF are associated with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation in a phase III intergroup trial (SWOG 9304). R Ladner, CM Ulrich, C Rankin, K Danenberg, P Danenberg, S Smalley, K Makar, J Benedetti, CD Blanke, HJ Lenz. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S9917

Southwest Oncology Group (SWOG) trial S9917: randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia (HGPIN). JR Marshall, CM Tangen, WA Sakr, DP Wood, SM Lippman, D Jarrad, DS Alberts, DL Berry, ED Crawford, IM Thompson. American Urological Association Annual Meeting (May 29-June 3, 2010, San Francisco, CA); accepted for oral presentation.

S9921

Southwest Oncology Group study 9921: prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. IM Thompson, B Ely, CM Tangen, MHA Hussain, DP Wood, GP Swanson, DI Quinn, TB Dorff, NA Dawson, NB Haas, ED Crawford. American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA); accepted for oral presentation.

S0000

Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill- Stevens, S Moody-Thomas, J Probstfield, S Hamilton, R Campbell, K Anderson, L Minasian. Society of Clinical Trials 2010 Annual Meeting (May 16-19, 2010, Baltimore, MD), accepted as poster presentation.

S0000

Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials. JM Harris- Talley, D Arney, K Anderson, JA Hartline. Society for Clinical Trials 2010 Meeting (May 16-19, 2010, Baltimore, MD), accepted as poster presentation.

S0000

Effect of vitamin E and selenium on incidence of physician- diagnosed COPD: the selenium and vitamin E cancer prevention trial (SELECT). PA Cassano, KB Arnold, K Guertin, AR Kristal, JJ Crowley JA Hartline, PJ Goodman, CM Tangen, LM Minasian, SM Lippman, CA Coltman, E Klein. American Thoracic Society 2010 Annual Meeting May 14-19, 2010, New Orleans, LA); accepted for oral presentation.

S0008

Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from the SWOG S0008 phase III randomized adjuvant trial. VK Sondak, R Tuthill, J Moon, JA Thompson, C Lao, B Redman, LE Flaherty. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0008

Minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma- associated genes is an independent prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. JA Sosman, J Moon, PY Liu, L Flaherty, MB Atkins, KA Margolin, J Kirkwood, V Sondak, for SWOG and ECOG. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0028

Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced (adv) urothelial cancer (UC), aged > 70 years (yrs): SWOG 0028. D Raghavan, C Tangen, C Moinpour, C Gotay, K Albain, S Louie, H-J Lenz, D Quinn, M Hussain, I Thompson. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0329

A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study. KE Bickel, J Moon, O Kucuk, RH Wheeler, S Urba, G Wolf, FP Worden. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for poster presentation.

S0421

Circulating tumor cell capture and analysis in a multi- center SWOG-coordinated prostate cancer trial. A Goldkorn, T Xu, B Lu, A Williams, LM Fink, CM Tangen, Y-C Tai, DI Quinn, P Twardowski, RJ Cote. American Society for Clinical Oncology, 2010 Annual Meeting,TIP (“Trials in Progress”) [June 4-8, 2010, Chicago, IL]; accepted as poster presentation.

S0430

Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). AF Schott, D Lew, WE Barlow, KS Albain, HK Chew, JL Wade, KS Lanier, HM Linden, GN Hortobagyi, RB Livingston. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S0438

Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438. K Margolin, J Moon, L Flaherty, C Lao, W Akerley, J Sosman, J Kirkwood, V Sondak. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S0727

A randomized phase II trial of combination gemcitabine + erlotinib + IMC-A12 (cixutumumab) vs. gemcitabine + erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer: Southwest Oncology Group study (SWOG S0727). PA Philip, B Goldman, RK Ramanathan, HJ Lenz, AM Lowy, RP Whitehead, S Iqbal, V Chung, JK Benedetti, CDBlanke. American Society for Clinical Oncology, 2010 Annual Meeting, TIP (“Trials in Progress”) [June 4-8, 2010, Chicago, IL]; accepted as poster presentation.

E2205

A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab followed by post-operative docetaxel cetuximab in patients with operable adenocarcinoma of the esophagus. MK Gibson, L Kleinberg, C Staley, P Catalano, F Song, MF Mulcahy, LP Leichman, AB Benson. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

4B951

Cell cycle regulatory protein alterations in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. S Lerner, W Stadler, S Groshen, J Cai, A Mitra, E Tuazon, D Skinner, D Raghavan, D Esrig, G Steinberg, C Hall, R Cote. American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA); accepted as poster presentation.


Got news to tell? Send it to communications@swog.org.